CD8A and melanoma: CSF1 inhibitors also showed additive effects with ACT therapies in preclinical melanoma studies, where anti-CSF1 dampened myeloid cell-mediated immunosuppression in the TME, permitting greater CD4+ and CD8+ T-cell infiltration into tumors and with improved functionality (124).